Photodynamic Therapy for Mesothelioma and Lung Cancer
Trial Summary
What is the purpose of this trial?
This phase I trial studies the side effects and how well light dosimetry system works during photodynamic therapy with porfimer sodium in treating participants with malignant mesothelioma , non-small cell lung cancer or any other malignancy with pleural disease undergoing surgery. Light dosimetry measures the amount of laser light given during photodynamic therapy. Photodynamic therapy uses a drug, such as porfimer sodium, that becomes active when it is exposed to light. The activated drug may kill tumor cells. Using light dosimetry for intraoperative photodynamic therapy may help doctors estimate how much light is delivered during photodynamic therapy and decide if the treatment should be stopped or continued.
Will I have to stop taking my current medications?
The trial does not specify if you need to stop taking your current medications. However, you cannot have had chemotherapy or radiotherapy within 4 weeks before joining the study.
What data supports the effectiveness of this treatment for mesothelioma and lung cancer?
Photodynamic therapy (PDT) has shown promise in treating lung cancer and mesothelioma. In a study with patients having malignant pleural mesothelioma, those with early-stage disease had a median survival of 21 months after receiving PDT, suggesting it may be more effective in earlier stages. Additionally, new photosensitizers have demonstrated high efficiency in killing mesothelioma cells in laboratory settings.12345
Is photodynamic therapy with porfimer sodium safe for humans?
Photodynamic therapy with porfimer sodium is generally safe, but it can cause some side effects like skin sensitivity to light, which can last for several weeks, and esophageal strictures (narrowing of the esophagus) in some cases. These side effects are not usually severe, but they are important to consider.678910
How is the treatment Porfimer Sodium unique for mesothelioma and lung cancer?
Porfimer Sodium is unique because it is a photosensitizing agent used in photodynamic therapy (PDT), which involves activating the drug with light to kill cancer cells. This treatment selectively targets tumor tissues and causes cell death by producing reactive oxygen species when exposed to specific light wavelengths, offering a different approach compared to traditional chemotherapy or radiation.136810
Research Team
Saikrishna S. Yendamuri
Principal Investigator
Roswell Park Cancer Institute
Eligibility Criteria
This trial is for adults with malignant mesothelioma, non-small cell lung cancer, or pleural disease who are undergoing surgery. They must be in fair to good physical condition (ECOG 0-2), agree to use birth control if applicable, and not have distant spread of the disease. People with low white blood cells or platelets, liver issues, uncontrolled illnesses like heart failure or infections, brain metastases, recent other treatments or investigational drugs can't join.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive porfimer sodium intravenously and undergo intraoperative photodynamic therapy (IO-PDT) via a light dosimetry system
Follow-up
Participants are monitored for safety and effectiveness after treatment
Treatment Details
Interventions
- Light Dosimetry
- Light Dosimetry for Intranoperative Therapy
- Porfimer Sodium
Find a Clinic Near You
Who Is Running the Clinical Trial?
Roswell Park Cancer Institute
Lead Sponsor
Lumeda,Inc.
Collaborator